Skip to content
BY 4.0 license Open Access Published by De Gruyter September 18, 2019

Actinomycin D for fibrosis management in ophthalmic implant surgery

  • Andreas Brietzke EMAIL logo , Thomas Eickner , Niels Grabow , Thomas Reske , Claudia Matschegewski , Rudolf Guthoff and Thomas Stahnke

Abstract

Implants that feature a drug delivery system loaded with antifibrotic active drugs provide a promising approach to address postoperative complications caused by fibrosis. This study is intended to clarify whether Actinomycin D has an impact specifically on components of the extracellular matrix (ECM) and its formation in human primary fibroblasts of the Tenon capsule (hTF). Furthermore, the suitability of this agent in poly(N-vinylpyrrolidone)- poly(methylmethacrylate)(PVP-co-PMMA) as a drug delivery model is evaluated in drug incorporation and release studies. RT-qPCR revealed a significant downregulation of the fibrotic marker genes ACTA2, COL1A1 and FN1 in cells stimulated with TGF- β1 and additionally treated with Actinomycin D. However, these findings could only be confirmed on α- SMA protein level. collagen I and Fibronectin synthesis stayed unaffected. The diffusion based incorporation of Actinomycin D into the polymer model proved to be very effective. The release of the agent was retarded with a slightly prolonged kinetic. These findings make Actinomycin D a promising antifibrotic agent in ophthalmic implant surgery.

Published Online: 2019-09-18
Published in Print: 2019-09-01

© 2019 by Walter de Gruyter Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Downloaded on 23.2.2024 from https://www.degruyter.com/document/doi/10.1515/cdbme-2019-0121/html
Scroll to top button